A personalized mRNA cancer vaccine developed by Moderna and Merck reduced recurrence risk in melanoma patients in a clinical trial.
A personalized mRNA vaccine reduced melanoma recurrence or death risk by 42 percent in a trial of over 1,100 patients with surgically removed high-risk melanoma.
- The mRNA vaccine reduces recurrence or death risk by 42 percent.
- The combination treatment reduced the risk of the cancer spreading by 38%.
- 82.2% of subjects receiving the vaccine and Keytruda remained cancer-free after two years.
- The trial involved 1,137 patients with surgically removed melanoma.
- The vaccine was tested against melanoma.
- The investigational mRNA-based neoantigen therapy is jointly developed by MSD and Moderna.
- The vaccine can be prepared and administered in six weeks.
- Prof Georgina Long described the findings as a foundational shift in cancer approach.
Outlets: ABC News Australia (Top), Ars Technica - All content, CBC | Top Stories News, Clarín, Courrier international, Efimerida ton Syntakton, El Financiero, El Universo, Financial Times, G4Media, Guardian Australia, Gulf News, HotNews.ro, International: Top News And Analysis, La Presse, La Stampa, La Vanguardia, MarketWatch, NBC News, Nature, New Scientist, The Independent, Times of Israel, Zerkalo, g1
Written by AI from the outlets' reporting and checked automatically; it can contain mistakes. How Daily Brief works · Privacy